NEWS & BLOG
Stay up to date with the latest news and updates from KCNQ2 Cure.
Update on Opakalim – Kv7 activator
Biohaven shared new data this week on their experimental epilepsy medicine opakalim, including an update involving a child with KCNQ2-DEE. In the six-month follow-up, the company reported that the child…
Guest Blog – Why We Drove 3 Hours to Donate Samples
Why We Drove 3 Hours to Donate Samples (And Why You Should Too!) When you are navigating a rare disease journey, you quickly learn that every drop of data counts.…
Establishing KCNQ2 p.G281R Mouse as a Preclinical Model for Therapeutic Discovery
KCNQ2 Cure is excited to announce a new KCNQ2‑DEE research grant, funded in partnership with CURE Epilepsy. Together, we are co-funding this Rare Epilepsy Partnership Award to support the development…
Breaking Down the Clinical Trial Process
Clinical trials are an essential part of therapeutic development. At each step, researchers take great care to ensure the treatments they are testing are both safe and effective. You may…
KCNQ2 Awareness Why We Recognize It in March
Channeling Hope: Why We Recognize KCNQ2 Awareness in March Each year in early March, our global community recognizes KCNQ2 Awareness Day on March 2 as part of KCNQ2 Awareness Week.…
Supporting Research for KCNQ2-Related Disorders
The KCNQ2 Biorepository Through our partnership with COMBINEDBrain, the KCNQ2 Cure Alliance has started to generate a collection of biological samples, called a biorepository. Different types of biological materials have…
Interested in Learning More About Gene Therapies?
KCNQ2 and Gene Therapy As genomics technologies continue to advance, so too has the potential of personalized treatments, including interventions that target specific genes. Because we know that variants in…
Expanded Access of Kv7.2 Channel Activators
Kv7.2 Channel Activators In many cases, KCNQ2-DEE is caused by reduced Kv7.2 potassium channel activity. Because of this, therapeutics that boost the activity of these channels are likely to be…
Praxis EMERALD Clinical Trial
KCNQ2 Cure hosted a webinar for the KCNQ2 community featuring a discussion with Praxis Precision Medicines. Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing therapies for disorders…
Reflections from the American Epilepsy Society Meeting 2025
Earlier this month, KCNQ2 Cure Alliance members attended the American Epilepsy Society (AES) meeting in Atlanta, Georgia. Our goal was to connect with scientists, clinicians, and industry partners to learn…
